Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 969 of 6351
-
Diabetes drug semaglutide tested as potential treatment for fatty liver disease NASH
Disease control OngoingSemaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided …
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can new brain stimulation patterns quiet stubborn tremors?
Disease control CompletedThis project aims to investigate novel ways to deliver brain stimulation to Essential Tremor (ET) patients by introducing software changes to their existing devices. The study team aims to investigate safety and efficacy of these new stimulation parameters in patients with ET.
Sponsor: University of Florida • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Gene test could tailor chemo for pancreatic cancer patients
Disease control Recruiting nowThis is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Can a smart pump make Post-Surgical pain relief safer?
Disease control OngoingTo meet the unmet need of better and safer pain relief for acute pain in the post-operative setting, a Vital-signs-integrated Patient-assisted Intravenous opioid Analgesia ("VPIA") Delivery System, with novel and intelligent software algorithms and specialised hardware was develo…
Phase 2/3 • Sponsor: KK Women's and Children's Hospital • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New combo therapy aims to shrink tumors in hard-to-treat cancers
Disease control OngoingBasket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors.
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for tough lung cancers: DS-1062a shows promise in early trial
Disease control CompletedThis is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
Phase 2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could an existing eczema drug help a rare skin condition?
Disease control OngoingNummular eczema (NE) is an idiopathic chronic inflammatory skin disease that occurs throughout all life periods. Diagnosis is made primarily clinically in correlation with histological findings. Treatment of NE is difficult. Standard treatment consists of the use of emollients, t…
Phase 2 • Sponsor: Technical University of Munich • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a blood pressure drug shield hearts from secondhand smoke damage?
Disease control Recruiting nowThis is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonge…
Phase 4 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for lymphoma patients after CAR T-Cell failure
Disease control CompletedThis study is a multicenter phase II trial including 2 cohorts of patients in Refractory/Relapse disease at least 1 month after CAR T-cells therapy: * cohort 1: DLBCL patients * cohort 2: PMBL, mantle cell lymphoma, transformed indolent NHL (t-iNHL) or iNHL CAR T-cells Refractor…
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Machine learning may forecast brain decline after head injury
Knowledge-focused CompletedThis study will look to validate predictive algorithms developed in a previous study where we collected relevant data from trauma registry and after using advanced signal-processing and machine-learning, determined prediction scores regarding neuroworsening and other outcomes fol…
Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New combo therapy shows promise for Tough-to-Treat colorectal cancer
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in participants with metastatic colorectal cancer. The study will also compare lenvatinib plus pembrolizumab with the standard of care treatmen…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Experimental combo targets HPV-Driven head and neck tumors
Disease control CompletedVERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Phase 2 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Could a love hormone help veterans beat alcohol addiction and PTSD?
Symptom relief CompletedThe primary objective of the proposed Stage II study is to examine the efficacy of oxytocin (OT) as compared to placebo in reducing (1) alcohol use disorder (AUD) symptoms, and (2) post-traumatic stress disorder (PTSD) symptoms among Veterans receiving COPE therapy (Concurrent Tr…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
New injection shows promise for long-term prevention of rare swelling disorder
Disease control CompletedThis phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC)
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for kids with aggressive brain cancer: drug aims to stop relapse
Disease control Recruiting nowDifluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Phase 2 • Sponsor: Giselle Sholler • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Immune cell therapy shows promise for Tough-to-Treat lymphoma
Disease control CompletedAB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial will enroll patients wit…
Phase 1/2 • Sponsor: Artiva Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
Disease control OngoingAdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibit…
Phase 2 • Sponsor: EpicentRx, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Can your own blood straighten the curve? PRP takes on Peyronie's
Disease control CompletedThe purpose of this study is to learn about the effects of Platelet-Rich Plasma (PRP) injection in men with Peyronie's Disease (PyD).
Phase 2 • Sponsor: University of Miami • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Mobile TB testing vans could catch hidden cases in slums
Knowledge-focused CompletedTB remains the foremost infectious disease killer globally. A startling statistic is that two out of every five TB cases globally (40%) remain undiagnosed and untreated. These 'missed' or undiagnosed cases are disproportionately concentrated in large peri-urban 'slums' and inform…
Sponsor: University of Cape Town • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
One-Stop shop: HIV prevention plus gender care shows promise
Prevention CompletedA study to assess the feasibility, acceptability, and preliminary impact of a multi-component strategy to improve pre-exposure prophylaxis (PrEP) uptake and adherence that integrates delivery of biomedical HIV prevention co-located with gender-affirming transgender care (hormonal…
Phase 2/3 • Sponsor: HIV Prevention Trials Network • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC